Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies
Cancer and cardiovascular diseases are the leading causes of death and morbidity worldwide. Strikingly, cardiovascular disorders are more common and more severe in cancer patients than in the general population, increasing incidence rates. In this context, it is vital to consider the anticancer effi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.690533/full |
| _version_ | 1819100504752390144 |
|---|---|
| author | Gabriel Silva Marques Borges Gabriel Silva Marques Borges Eduardo Burgarelli Lages Eduardo Burgarelli Lages Pierre Sicard Pierre Sicard Lucas Antônio Miranda Ferreira Sylvain Richard Sylvain Richard |
| author_facet | Gabriel Silva Marques Borges Gabriel Silva Marques Borges Eduardo Burgarelli Lages Eduardo Burgarelli Lages Pierre Sicard Pierre Sicard Lucas Antônio Miranda Ferreira Sylvain Richard Sylvain Richard |
| author_sort | Gabriel Silva Marques Borges |
| collection | DOAJ |
| description | Cancer and cardiovascular diseases are the leading causes of death and morbidity worldwide. Strikingly, cardiovascular disorders are more common and more severe in cancer patients than in the general population, increasing incidence rates. In this context, it is vital to consider the anticancer efficacy of a treatment and the devastating heart complications it could potentially cause. Oncocardiology has emerged as a promising medical and scientific field addressing these aspects from different angles. Interestingly, nanomedicine appears to have great promise in reducing the cardiotoxicity of anticancer drugs, maintaining or even enhancing their efficacy. Several studies have shown the benefits of nanocarriers, although with some flaws when considering the concept of oncocardiology. Herein, we discuss how preclinical studies should be designed as closely as possible to clinical protocols, considering various parameters intrinsic to the animal models used and the experimental protocols. The sex and age of the animals, the size and location of the tumors, the doses of the nanoformulations administered, and the acute vs. the long-term effects of treatments are essential aspects. We also discuss the perspectives offered by non-invasive imaging techniques to simultaneously assess both the anticancer effects of treatment and its potential impact on the heart. The overall objective is to accelerate the development and validation of nanoformulations through high-quality preclinical studies reproducing the clinical conditions. |
| first_indexed | 2024-12-22T01:03:50Z |
| format | Article |
| id | doaj.art-fae1ab95d8184888bb31c425126476c5 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-22T01:03:50Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-fae1ab95d8184888bb31c425126476c52022-12-21T18:44:08ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-06-01810.3389/fcvm.2021.690533690533Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical StudiesGabriel Silva Marques Borges0Gabriel Silva Marques Borges1Eduardo Burgarelli Lages2Eduardo Burgarelli Lages3Pierre Sicard4Pierre Sicard5Lucas Antônio Miranda Ferreira6Sylvain Richard7Sylvain Richard8Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilPhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, FranceDepartamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilPhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, FrancePhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, FranceIPAM, BioCampus, CNRS, INSERM, Université de Montpellier, Montpellier, FranceDepartamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilPhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, FranceIPAM, BioCampus, CNRS, INSERM, Université de Montpellier, Montpellier, FranceCancer and cardiovascular diseases are the leading causes of death and morbidity worldwide. Strikingly, cardiovascular disorders are more common and more severe in cancer patients than in the general population, increasing incidence rates. In this context, it is vital to consider the anticancer efficacy of a treatment and the devastating heart complications it could potentially cause. Oncocardiology has emerged as a promising medical and scientific field addressing these aspects from different angles. Interestingly, nanomedicine appears to have great promise in reducing the cardiotoxicity of anticancer drugs, maintaining or even enhancing their efficacy. Several studies have shown the benefits of nanocarriers, although with some flaws when considering the concept of oncocardiology. Herein, we discuss how preclinical studies should be designed as closely as possible to clinical protocols, considering various parameters intrinsic to the animal models used and the experimental protocols. The sex and age of the animals, the size and location of the tumors, the doses of the nanoformulations administered, and the acute vs. the long-term effects of treatments are essential aspects. We also discuss the perspectives offered by non-invasive imaging techniques to simultaneously assess both the anticancer effects of treatment and its potential impact on the heart. The overall objective is to accelerate the development and validation of nanoformulations through high-quality preclinical studies reproducing the clinical conditions.https://www.frontiersin.org/articles/10.3389/fcvm.2021.690533/fullanticancer drugscardiotoxicitynanoformulationsnon-invasive imagingechographyphotoacoustic |
| spellingShingle | Gabriel Silva Marques Borges Gabriel Silva Marques Borges Eduardo Burgarelli Lages Eduardo Burgarelli Lages Pierre Sicard Pierre Sicard Lucas Antônio Miranda Ferreira Sylvain Richard Sylvain Richard Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies Frontiers in Cardiovascular Medicine anticancer drugs cardiotoxicity nanoformulations non-invasive imaging echography photoacoustic |
| title | Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies |
| title_full | Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies |
| title_fullStr | Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies |
| title_full_unstemmed | Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies |
| title_short | Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies |
| title_sort | nanomedicine in oncocardiology contribution and perspectives of preclinical studies |
| topic | anticancer drugs cardiotoxicity nanoformulations non-invasive imaging echography photoacoustic |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.690533/full |
| work_keys_str_mv | AT gabrielsilvamarquesborges nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT gabrielsilvamarquesborges nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT eduardoburgarellilages nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT eduardoburgarellilages nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT pierresicard nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT pierresicard nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT lucasantoniomirandaferreira nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT sylvainrichard nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies AT sylvainrichard nanomedicineinoncocardiologycontributionandperspectivesofpreclinicalstudies |